Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HTR2A | P28223 | 6/20 | 0.60 |
| ▸ | HTR6 | P50406 | 3/20 | 0.60 |
| ▸ | NFE2L2 | Q16236 | 8/20 | 0.48 |
| ▸ | GRM5 | P41594 | 2/20 | 0.46 |
| ▸ | HTR1A | P08908 | 1/20 | 0.44 |
| ▸ | DRD2 | P14416 | 1/20 | 0.44 |
| ▸ | HTR7 | P34969 | 1/20 | 0.44 |
| ▸ | HTR2C | P28335 | 1/20 | 0.39 |
| ▸ | HTR2B | P41595 | 1/20 | 0.39 |
| ▸ | KCNH2 | Q12809 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4232976 | 0.89 | HTR2A (0.47) | HTR2AHTR6NFE2L2GRM5HTR1A | |
| SCHEMBL19327019 | 0.86 | HTR2A (0.62) | HTR2AHTR6NFE2L2GRM5HTR1A | |
| SCHEMBL2198627 | 0.84 | HTR2A (0.60) | HTR2AHTR6NFE2L2GRM5HTR1A | |
| SCHEMBL2198404 | 0.84 | HTR2A (0.60) | HTR2AHTR6NFE2L2GRM5HTR1A | |
| SCHEMBL2195845 | 0.81 | HTR2A (0.56) | HTR2AHTR6NFE2L2GRM5HTR1A | |
| SCHEMBL18796178 | 0.79 | HTR2A (0.54) | HTR2AHTR6NFE2L2GRM5HTR2C | |
| SCHEMBL4701358 | 0.78 | ALDH1A1 (0.39) | HTR2AHTR6HTR1ADRD2HTR7 | |
| SCHEMBL4563072 | 0.77 | HDAC1 (0.46) | HTR2AHTR6NFE2L2HTR2CHTR2B | |
| SCHEMBL10295090 | 0.76 | HTR6 (0.52) | HTR2AHTR6GRM5HTR1ADRD2 | |
| SCHEMBL19327036 | 0.75 | HTR6 (0.70) | HTR2AHTR6GRM5HTR1ADRD2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2120950-B1 | USE OF QUINOLINE DERIVATIVES IN THE TREATMENT OF PAIN | GLAXO GROUP LTD (GB) | 2012-07-04 | — | — | EP | disclosed |
| EP-2120950-B1 | USE OF QUINOLINE DERIVATIVES IN THE TREATMENT OF PAIN | GLAXO GROUP LTD (GB) | 2012-07-04 | — | — | EP | disclosed |
| US-20100041672-A1 | USE OF QUINOLINE DERIVATIVES IN THE TREATMENT OF PAIN AND IRRITABLE BOWEL SYNDROME | GLAXO GROUP LIMITED (GB) | 2010-02-18 | — | — | US | disclosed |
| US-20100041672-A1 | USE OF QUINOLINE DERIVATIVES IN THE TREATMENT OF PAIN AND IRRITABLE BOWEL SYNDROME | GLAXO GROUP LIMITED (GB) | 2010-02-18 | — | — | US | disclosed |
| US-20100041672-A1 | USE OF QUINOLINE DERIVATIVES IN THE TREATMENT OF PAIN AND IRRITABLE BOWEL SYNDROME | GLAXO GROUP LIMITED (GB) | 2010-02-18 | — | — | US | disclosed |
| EP-2120950-A1 | USE OF QUINOLINE DERIVATIVES IN THE TREATMENT OF PAIN AND IRRITABLE BOWEL SYNDROME | Glaxo Group Limited (GB) | 2009-11-25 | — | — | EP | disclosed |
| WO-2008113818-A1 | USE OF QUINOLINE DERIVATIVES IN THE TREATMENT OF PAIN AND IRRITABLE BOWEL SYNDROME | GLAXO GROUP LIMITED (GB) | 2008-09-25 | — | — | WO | disclosed |
| WO-2008113818-A1 | USE OF QUINOLINE DERIVATIVES IN THE TREATMENT OF PAIN AND IRRITABLE BOWEL SYNDROME | GLAXO GROUP LIMITED (GB) | 2008-09-25 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100041672-A1 | USE OF QUINOLINE DERIVATIVES IN THE TREATMENT OF PAIN AND IRRITABLE BOWEL SYNDROME | HTR6, TPH1, HRH2 | HTR2A 16/4885HTR6 1/4885NFE2L2 2262/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.